RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Ono Pharmaceutical Co Stock

Ono Pharmaceutical Co Liabilities 2024

Ono Pharmaceutical Co Liabilities

120.71 B JPY

Ticker

4528.T

ISIN

JP3197600004

WKN

859650

In 2024, Ono Pharmaceutical Co's total liabilities amounted to 120.71 B JPY, a 44.91% difference from the 83.3 B JPY total liabilities in the previous year.

Ono Pharmaceutical Co Aktienanalyse

What does Ono Pharmaceutical Co do?

Ono Pharmaceutical Co Ltd is a Japanese company specialized in the development and marketing of innovative medications. It has a long history, being founded in 1717. Originally, it was a Chinese medicine business, but since its establishment in 1924, Ono Pharmaceutical has focused on the development of modern medications. The company's business model is based on research and development of medications. Ono Pharmaceutical has several branches in different countries and works closely with research institutions and universities to develop groundbreaking medications. The company is committed to providing innovative therapies to patients worldwide. Ono Pharmaceutical specializes in several areas, including oncology, immunology, neurology, and diabetes. In oncology, the company has launched several medications, including Opdivo and Sprycel, used for the treatment of various forms of cancer. Opdivo is an immunooncological medication that shows great promise and is used worldwide. In immunology, Ono Pharmaceutical has developed a range of medications, including Nivolumab, used for the treatment of various autoimmune diseases such as rheumatoid arthritis. Ono Pharmaceutical has also developed medications for influenza and other types of infections. In the field of neurology, the company has developed medications used for pain treatment, including the compound Fauldopamine. Despite the discovery of Fauldopamine, which is considered suitable for pain treatment, no final decision has been made regarding the application of this medication. In diabetes research, Ono Pharmaceutical has developed various medications used for the treatment of diabetes, including Alogliptin and Canagliflozin. These medications help diabetics better control their blood sugar levels and alleviate the symptoms of this disease. Ono Pharmaceutical has also launched numerous products used in different areas, such as Desitin, a cream for the treatment of skin disorders, or Minon, a skincare line. The company places great importance on collaboration and innovation to provide highly effective medications to patients. Ono Pharmaceutical is committed to expanding its presence in the global market and developing further innovative therapies to improve people's lives. Ono Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Ono Pharmaceutical Co's Liabilities

Ono Pharmaceutical Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Ono Pharmaceutical Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Ono Pharmaceutical Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Ono Pharmaceutical Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Ono Pharmaceutical Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Ono Pharmaceutical Co stock

What is the level of liabilities of Ono Pharmaceutical Co this year?

Ono Pharmaceutical Co has a debt balance of 120.71 B JPY this year.

What were the liabilities of Ono Pharmaceutical Co compared to the previous year?

The liabilities of Ono Pharmaceutical Co have increased by 44.91% increased compared to the previous year.

What are the consequences of high debt for investors of Ono Pharmaceutical Co?

High liabilities can pose a risk for investors of Ono Pharmaceutical Co, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Ono Pharmaceutical Co?

Low liabilities mean that Ono Pharmaceutical Co has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Ono Pharmaceutical Co affect the company?

An increase in liabilities of Ono Pharmaceutical Co can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Ono Pharmaceutical Co affect the company?

A decrease in the liabilities of Ono Pharmaceutical Co can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Ono Pharmaceutical Co?

Some factors that can influence the liabilities of Ono Pharmaceutical Co include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Ono Pharmaceutical Co so important for investors?

The liabilities of Ono Pharmaceutical Co are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Ono Pharmaceutical Co take to modify the liabilities?

To change its liabilities, Ono Pharmaceutical Co can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Ono Pharmaceutical Co pay?

Over the past 12 months, Ono Pharmaceutical Co paid a dividend of 80 JPY . This corresponds to a dividend yield of about 4.91 %. For the coming 12 months, Ono Pharmaceutical Co is expected to pay a dividend of 86.14 JPY.

What is the dividend yield of Ono Pharmaceutical Co?

The current dividend yield of Ono Pharmaceutical Co is 4.91 %.

When does Ono Pharmaceutical Co pay dividends?

Ono Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Ono Pharmaceutical Co?

Ono Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Ono Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 86.14 JPY are expected. This corresponds to a dividend yield of 5.28 %.

In which sector is Ono Pharmaceutical Co located?

Ono Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ono Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ono Pharmaceutical Co from 12/1/2024 amounting to 40 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Ono Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Ono Pharmaceutical Co in the year 2023?

In the year 2023, Ono Pharmaceutical Co distributed 77 JPY as dividends.

In which currency does Ono Pharmaceutical Co pay out the dividend?

The dividends of Ono Pharmaceutical Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Ono Pharmaceutical Co

Our stock analysis for Ono Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ono Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.